A Phase II randomized controlled trial published in the Journal of Cannabis Research found that a cannabis-based formulation is a credible benzodiazepine alternative for sleep, matching lorazepam on the Pittsburgh Sleep Quality Index over four weeks under double-blind conditions. PSQI scores dropped by 9 points in the cannabis group and 8.3 in the lorazepam group, both falling below the clinical insomnia threshold, with no significant differences in liver, kidney, or cardiac safety measures. Dr. Benjamin Caplan reads the trial carefully, identifies what it proves and what it cannot yet answer, and explains what it means for patients in Massachusetts who are trying to get off sleeping pills.